$2.11
+0.01
(+0.48%)▲
Live
1.18%
Downside
Day's Volatility :2.55%
Upside
1.38%
49.53%
Downside
52 Weeks Volatility :83.04%
Upside
66.4%
Period | Mersana Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 5.0% | 3.6% | 0.0% |
6 Months | -33.33% | 10.2% | 0.0% |
1 Year | 44.83% | 19.6% | 0.0% |
3 Years | -75.0% | 16.8% | -23.0% |
Market Capitalization | 258.8M |
Book Value | $0.07 |
Earnings Per Share (EPS) | -0.85 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -1110.12% |
Return On Assets TTM | -26.3% |
Return On Equity TTM | -213.33% |
Revenue TTM | 29.9M |
Revenue Per Share TTM | 0.25 |
Quarterly Revenue Growth YOY | -78.5% |
Gross Profit TTM | -146.8M |
EBITDA | -101.4M |
Diluted Eps TTM | -0.85 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.71 |
EPS Estimate Next Year | -0.7 |
EPS Estimate Current Quarter | -0.17 |
EPS Estimate Next Quarter | -0.15 |
What analysts predicted
Upside of 208.06%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 10.6M | ↓ 39.62% |
Net Income | -64.3M | ↑ 66.01% |
Net Profit Margin | -606.54% | ↓ 385.92% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 42.1M | ↑ 297.61% |
Net Income | -27.2M | ↓ 57.67% |
Net Profit Margin | -64.57% | ↑ 541.97% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 828.0K | ↓ 98.03% |
Net Income | -88.4M | ↑ 225.05% |
Net Profit Margin | -10.7K% | ↓ 10612.24% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 43.0K | ↓ 94.81% |
Net Income | -169.2M | ↑ 91.4% |
Net Profit Margin | -393.5K% | ↓ 382823.19% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 26.6M | ↑ 61716.28% |
Net Income | -207.5M | ↑ 22.66% |
Net Profit Margin | -780.78% | ↑ 392719.22% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 36.9M | ↑ 38.65% |
Net Income | -171.7M | ↓ 17.28% |
Net Profit Margin | -465.8% | ↑ 314.98% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.8M | ↓ 46.88% |
Net Income | -57.1M | ↑ 24.53% |
Net Profit Margin | -732.45% | ↓ 420.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.7M | ↑ 36.55% |
Net Income | -54.3M | ↓ 4.97% |
Net Profit Margin | -509.73% | ↑ 222.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.7M | ↓ 27.75% |
Net Income | -41.7M | ↓ 23.3% |
Net Profit Margin | -541.13% | ↓ 31.4% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.7M | ↑ 39.01% |
Net Income | -19.5M | ↓ 53.08% |
Net Profit Margin | -182.64% | ↑ 358.49% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 9.2M | ↓ 13.61% |
Net Income | -19.3M | ↓ 1.22% |
Net Profit Margin | -208.83% | ↓ 26.19% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.3M | ↓ 75.2% |
Net Income | -24.3M | ↑ 25.7% |
Net Profit Margin | -1.1K% | ↓ 849.52% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 78.5M | ↓ 39.94% |
Total Liabilities | 69.7M | ↑ 14.8% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 107.5M | ↑ 36.99% |
Total Liabilities | 29.2M | ↓ 58.08% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 273.4M | ↑ 154.23% |
Total Liabilities | 45.3M | ↑ 55.06% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 206.1M | ↓ 24.61% |
Total Liabilities | 84.4M | ↑ 86.2% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 334.3M | ↑ 62.21% |
Total Liabilities | 242.3M | ↑ 187.17% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 226.1M | ↓ 32.39% |
Total Liabilities | 189.2M | ↓ 21.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 296.2M | ↓ 11.41% |
Total Liabilities | 231.9M | ↓ 4.29% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 311.0M | ↑ 5.0% |
Total Liabilities | 221.2M | ↓ 4.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 262.9M | ↓ 15.46% |
Total Liabilities | 210.7M | ↓ 4.74% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 226.1M | ↓ 14.01% |
Total Liabilities | 189.2M | ↓ 10.23% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 198.4M | ↓ 12.25% |
Total Liabilities | 170.4M | ↓ 9.92% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 179.1M | ↓ 9.7% |
Total Liabilities | 170.7M | ↑ 0.18% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -55.2M | ↑ 29.38% |
Investing Cash Flow | 87.2M | ↓ 187.52% |
Financing Cash Flow | 1.1M | ↓ 98.45% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -67.7M | ↑ 22.69% |
Investing Cash Flow | -27.3M | ↓ 131.3% |
Financing Cash Flow | 97.7M | ↑ 9082.71% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -74.7M | ↑ 10.26% |
Investing Cash Flow | 37.0M | ↓ 235.66% |
Financing Cash Flow | 230.4M | ↑ 135.83% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -140.0M | ↑ 87.41% |
Investing Cash Flow | -648.0K | ↓ 101.75% |
Financing Cash Flow | 63.6M | ↓ 72.38% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -49.4M | ↓ 64.74% |
Investing Cash Flow | -152.7M | ↑ 23467.28% |
Financing Cash Flow | 153.0M | ↑ 140.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -29.0M | ↓ 43.38% |
Investing Cash Flow | 1.4M | ↓ 103.07% |
Financing Cash Flow | 21.5M | ↓ 48.02% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -61.8M | ↑ 113.18% |
Investing Cash Flow | -5.4M | ↓ 489.61% |
Financing Cash Flow | 73.2M | ↑ 239.6% |
Sell
Neutral
Buy
Mersana Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Mersana Therapeutics Inc | 7.97% | -33.33% | 44.83% | -75.0% | 22.81% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Mersana Therapeutics Inc | NA | NA | 0.0 | -0.71 | -2.13 | -0.26 | NA | 0.07 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Mersana Therapeutics Inc | Buy | $258.8M | 22.81% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Mersana Therapeutics Inc
Revenue is down for the last 3 quarters, 10.70M → 2.29M (in $), with an average decrease of 44.4% per quarter
Netprofit is down for the last 2 quarters, -19.30M → -24.26M (in $), with an average decrease of 25.7% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 44.7%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 119.8%
EcoR1 Capital, LLC
VR Adviser, LLC
Nextech Invest AG
Bain Capital Life Sciences Investors, LLC
BlackRock Inc
Vanguard Group Inc
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Organization | Mersana Therapeutics Inc |
Employees | 123 |
CEO | Dr. Martin H. Huber M.D. |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$2.11
+0.48%
Invesco Bulletshares 2025 Hi
$2.11
+0.48%
Schwab International Dividend Equity Etf
$2.11
+0.48%
Blockchain Coinvestors Acquisition Corp.
$2.11
+0.48%
Allgiant Travel Company
$2.11
+0.48%
Rogers Corp
$2.11
+0.48%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$2.11
+0.48%
Iheartmedia
$2.11
+0.48%
Lightpath Technologies Inc
$2.11
+0.48%